GlassScriptPhysician profile
Aaron L Anderson
NPI 1780769323
$2,264.15
in general payments reported to CMS, 2019-2025
43 companies · $654 in 2025
The $654 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.59 · 2022: $324 · 2023: $526 · 2024: $703 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.99 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $224.37 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $142.31 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $125.65 | 2023-2025 | |
| Genentech USA, INC. | $122.31 | 2022-2025 | Polivy, Columvi, Gazyva |
| Astrazeneca Pharmaceuticals LP | $120.18 | 2022-2025 | Enhertu, Tagrisso |
| Daiichi Sankyo INC. | $112.96 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $86.90 | 2022-2025 | |
| Genzyme Corporation | $71.90 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $69.98 | 2022-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $65.90 | 2023-2025 | Keytruda, Lynparza |
| Blueprint Medicines Corporation | $62.15 | 2021-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $62.02 | 2022-2025 | Fruzaqla |
| Seagen INC. | $59.31 | 2022-2023 | Padcev |
| Incyte Corporation | $54.96 | 2023-2025 | Jakafi, Niktimvo |
| Bayer Healthcare Pharmaceuticals INC. | $53.66 | 2023-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $51.31 | 2022-2024 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $50.69 | 2022-2024 | Opdualag, Opdivo |
| Gilead Sciences, INC. | $50.42 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $49.50 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $40.84 | 2024-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $40.61 | 2023-2025 | Clonoseq |
| Tolmar Pharmaceuticals, INC. | $40.23 | 2021-2022 | |
| Amgen INC. | $38.73 | 2023 | Xgeva, Nplate, Vectibix |
| Ipsen Biopharmaceuticals, INC | $34.72 | 2023-2024 | Onivyde, Tazverik |
| Eisai INC. | $34.36 | 2024-2025 | |
| Astellas Pharma US INC | $32.58 | 2023-2025 | Xtandi, Padcev |
| Stemline Therapeutics INC. | $32.11 | 2023-2024 | Orserdu |
| Servier Pharmaceuticals LLC | $31.02 | 2022-2024 | |
| Taiho Oncology, INC. | $28.79 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $27.93 | 2023 | |
| Morphosys, US INC. | $23.86 | 2023 | Monjuvi |
| Sobi, INC | $23.66 | 2025 | |
| Syndax Pharmaceuticals, INC. | $22.44 | 2025 | |
| Pharmaessentia USA Corporation | $20.98 | 2025 | Besremi |
| Lilly USA, LLC | $20.41 | 2024 | Jaypirca, Verzenio |
| Mirati Therapeutics, INC. | $20.26 | 2023 | Krazati |
| G1 Therapeutics, INC. | $18.29 | 2023 | Cosela |
| Geron Corporation | $17.37 | 2025 | Rytelo |
| Immunogen, INC. | $17.20 | 2024 | Elahere |
| Glaxosmithkline, LLC. | $16.79 | 2024 | Jemperli, Zejula |
| Rigel Pharmaceuticals, INC. | $15.53 | 2024 | Tavalisse, Rezlidhia |
| Cti Biopharma Corp. | $14.76 | 2023 | Vonjo |
| Puma Biotechnology, INC. | $14.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.